Asset

  • No.

    100

  • Asset Title

    TAG72 CAR T Asset and Tethered IL-12 platform

  • Organization

    City of Hope

  • Product Type

    Cell therapy

  • Therapeutic Area

    Oncology

  • Development Stage

    Phase 1

  • Technical Summary

    • This asset has demonstrated that aberrantly glycosylated cell surface proteins on tumor cells are amenable CAR targets.

    •  Tumor-associated glycoprotein 72 (TAG72) antigen is the sialyl-Tn found on multiple O-glycoproteins expressed at high levels on the surface of several cancer types, including ovarian cancer. Here, we developed a humanized TAG72-specific CAR containing a 4-1BB intracellular co-stimulatory signaling domain (TAG72-BBz).

    • TAG72-BBz CAR T cells showed potent antigen-dependent cytotoxicity and cytokine production against multiple TAG72+ ovarian cancer cell lines and patient-derived ovarian cancer ascites.

    • Using in vivo xenograft models of peritoneal ovarian tumors, regional intraperitoneal delivery of TAG72-BBz CAR T cells significantly reduced tumor growth, extended overall survival of mice, and was further improved with repeat infusions of CAR T cells. However, reduced TAG72 expression was observed in early recurring tumors, which coincided with a lack of T cell persistence.

    • Inventors demonstrate efficacy with TAG72-CAR T cells in ovarian cancer, warranting further investigations as a CAR T cell therapeutic strategy for this disease.

  • Patent

    US20210308184A1
    WO2020028721A1

  • Publication

    Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells, Front Immunol (2018)

  • Attachment

TOP